shelf(0)

No. 035 · Mind · Sleep Peptide

DSIP

Delta sleep-inducing peptideEmideltideDeltaran

A Tier A · Controlled human trials how tiers work →
  • Not FDA approved
  • WADA — not listed
Compare Cite
9 residues C35H48N10O15
O O O O H O O O O H O O H O O O O H O N H N H N 2 H N H N H N H N H N H N H N H

2D structure from PubChem CID 68816 (Delta Sleep-Inducing Peptide), matched by molecular formula. Hydrogens on carbon are implied.

DSIP sequence fingerprint
  • Nonpolar 6
  • Polar 1
  • Negative charge 2

Each dot is a residue placed around the ring from N- to C-terminus; its distance from the centre reflects its chemistry.

01

Quick answers

What is DSIP?
Delta sleep-inducing peptide is a nonapeptide isolated from rabbit cerebral venous blood and characterized in 1977, named for its apparent delta-sleep-promoting effect.
How strong is the evidence for DSIP?
Tier A (controlled human trials) on the peptidemeta evidence scale. Small double-blind, placebo-controlled trials in chronic insomnia (e.g. Bes et al. 1992, n=16) found weak or no meaningful benefit; registered as a medicine in Russia but not FDA/EMA-approved.
Is DSIP FDA-approved?
No. DSIP is not approved by the FDA for any use. Outside the US: Russia — Deltaran® intranasal (registered 2016) for stress-related states and alcohol withdrawal.
Is DSIP banned in sport?
No. DSIP is not on the World Anti-Doping Agency Prohibited List.
How does DSIP work?
DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) has no identified gene, precursor protein, or specific receptor, so its mechanism and physiological role remain unresolved. Animal studies report effects on sleep, stress hormones, neurotransmitter levels, and opioid-related behaviors.
What is known about the safety of DSIP?
Human safety data are limited to small trials from the 1980s-1990s. Rapidly degraded by blood peptidases.

Last reviewed · editorial policy · markdown

02

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER A — At least one published randomized controlled trial in humans.

Small double-blind, placebo-controlled trials in chronic insomnia (e.g. Bes et al. 1992, n=16) found weak or no meaningful benefit; registered as a medicine in Russia but not FDA/EMA-approved.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

03

At a glance

Residues
9 amino acids, N→C
Molecular weight
848.8 Da
Formula
C35H48N10O15
Discovered
1977 Isolated from rabbit blood during induced sleep and characterized by Schoenenberger and Monnier (PNAS 1977).
Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved
Other approvals
  • Russia — Deltaran® intranasal (registered 2016) for stress-related states and alcohol withdrawal
WADA
Not on the Prohibited List
04

Sequence

N → C · 9 residues · hover, tap, or use arrow keys to inspect

05

Overview

Delta sleep-inducing peptide is a nonapeptide isolated from rabbit cerebral venous blood and characterized in 1977, named for its apparent delta-sleep-promoting effect. Its natural role remains unclear, and controlled human trials found weak or inconsistent effects on sleep.

Research status Small double-blind placebo-controlled insomnia trials (1980s-1992) with weak or inconsistent results; registered in Russia as Deltaran (intranasal) for stress-related states and alcohol withdrawal

06

Mechanism

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) has no identified gene, precursor protein, or specific receptor, so its mechanism and physiological role remain unresolved. Animal studies report effects on sleep, stress hormones, neurotransmitter levels, and opioid-related behaviors.

07

Effects reported in research

Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.

  • Delta-sleep promotion reported in early animal studies
  • Shorter sleep latency in one small controlled insomnia trial
  • Reported effects on stress-related hormones (mostly animal data)
  • Studied for stress-related states and alcohol withdrawal
08

Safety & unknowns

Human safety data are limited to small trials from the 1980s-1990s. Rapidly degraded by blood peptidases. Not FDA-approved. Registered in Russia as Deltaran® intranasal (2016).

Unknowns. Trial safety data apply to the populations, formulations and conditions studied.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

09

Studies [1]

  1. Clinical trial 1992

    Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study

    Bes F, Hofman W, Schuur J, et al. Neuropsychobiology

    In a double-blind, placebo-controlled, matched-pairs study of 16 chronic insomniacs, intravenous DSIP gave slightly higher sleep efficiency and shorter sleep latency, but effects were weak and subjective sleep quality did not change; the authors concluded short-term DSIP is unlikely to be of major benefit.

    [pubmed] [doi]

11

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

12

Cite this entry

$ cite --format=apa

peptidemeta. (2026). DSIP. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/dsip/

$ cite --format=bibtex 
@misc{peptidemeta-dsip,
  title = {DSIP},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/dsip/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open